David H Johnson
Affiliation: Vanderbilt University
- Evarts A. Graham and the first pneumonectomy for lung cancerLeora Horn
Division of Hematology and Oncology, Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Nashville, TN 37232 6307, USA
J Clin Oncol 26:3268-75. 2008
- Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyLuigi Moretti
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Oncologist 14:1106-15. 2009..Here, we investigated the association between different clinicopathological features and postoperative therapy and local control and survival in patients with resected pN2 NSCLC...
- Identifying barriers associated with enrollment of patients with lung cancer into clinical trialsLeora Horn
Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
Clin Lung Cancer 14:14-8. 2013..Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer...
- A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancerRobert Mutter
Vanderbilt University Medical Center, Nashville, Tennessee and University of Texas Southwestern Medical Center, Dallas, Texas, USA
Clin Cancer Res 15:2158-65. 2009..Cyclooxygenase (COX)-2 up-regulation plays an important role in the pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity and radiosensitivity of tumor cells in preclinical trials...
- Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cellsSergey V Novitskiy
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, 220 Pierce Avenue, Nashville, TN 37232, USA
J Thorac Oncol 5:1410-5. 2010..The purpose of the study was to elucidate the molecular mechanisms responsible for the development of neutropenia during the combination treatment...
- Update on new drugs in small cell lung cancerLeora Horn
Vanderbilt Ingram Cancer Center, Division of Heamology and Medical Oncology, Nashville, TN 37232, USA
Expert Opin Investig Drugs 20:441-5. 2011..Five-year survival is approximately 25% for patients with limited stage disease and 1 -- 2% for patients with extensive stage disease and has noti mproved in almost two decades...
- Targeting the eicosanoid pathway in non-small-cell lung cancerLeora Horn
Vanderbilt University School of Medicine, Vanderbilt Ingram Cancer Center, Division of Hematology and Medical Oncology, 2220 Pierce Avenue, Nashville, TN 37232, USA
Expert Opin Ther Targets 13:675-88. 2009..Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers...
- American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy
Vanderbilt University Medical Center, Nashville, TN, USA
J Clin Oncol 29:2121-7. 2011....
- A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology GroupLeora Horn
Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
J Thorac Oncol 4:527-33. 2009....
- Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United StatesLeora Horn
Vanderbilt Ingram Cancer Center, Nashville, TN, USA
J Clin Oncol 29:3932-8. 2011....
- Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancerDavid H Johnson
J Natl Cancer Inst 99:415-8. 2007
- EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancerSarita Dubey
University of California, San Francisco, San Francisco, California 94115, USA
J Thorac Oncol 1:406-12. 2006..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)...
- Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
J Thorac Oncol 1:441-6. 2006..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy...
- Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10Carmela Pepe
Division of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
J Clin Oncol 25:1553-61. 2007..This retrospective study evaluated the influence of age on survival, adjuvant chemotherapy delivery, and toxicity in National Cancer Institute of Canada (NCIC) Clinical Trials Group study JBR.10...
- Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599Corey Langer
Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 25:418-23. 2007..PS-2 patients on ECOG 1594 had a median survival (MS) of only 4.1 months and 1-year overall survival (OS) of 19%. Three percent had grade 5 toxicity...
- Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590Daniel B Costa
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
Lung Cancer 56:97-103. 2007..This is the first comprehensive study of this transcription factor in patients with NSCLC...
- PDGFR-beta expression in small cell lung cancer patientsEric T Shinohara
Department of Medicine, Abington Memorial Hospital, Abington, PA, USA
Int J Radiat Oncol Biol Phys 67:431-7. 2007..Data in non-small-cell cancer cell lines have suggested that PDGFR is a therapeutic target for drug development. In the current study PDGFR-beta expression and prognostic value in small cell lung cancer (SCLC) was investigated...
- Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch
Thoracic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:313-8. 2007..On the basis of improved outcomes in other subsets of stage III NSCLC, this trial tested the feasibility of induction chemoradiotherapy for SS NSCLC...
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerAlan Sandler
Vanderbilt University, Nashville, TN, USA
N Engl J Med 355:2542-50. 2006..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
- Novel strategies for the treatment of lung cancer: modulation of eicosanoidsMichael G Backlund
J Clin Oncol 26:825-7. 2008
- Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancerCarolyn Cao
Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 5671, USA
Cancer Res 66:11409-15. 2006..Clinical trials are needed to determine the potential of this combination therapy in patients with locally advanced lung cancer...
- Did targeted therapy fail cyclooxygenase too?Ildiko Csiki
J Clin Oncol 24:4798-800. 2006
- The rationale for adjuvant chemotherapy in stage I non-small cell lung cancerLeora Horn
Division of Hematology and Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
J Thorac Oncol 2:377-83. 2007..The treatment algorithm is based on currently available tumor- and host-related factors that affect prognosis...
- Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsJeffrey M Albert
Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Clin Cancer Res 13:3033-42. 2007..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation...
- Targeted therapy in non-small cell lung cancer: myth or realityDavid H Johnson
Division of Hematology and Oncology, Vanderbilt Ingram Comprehensive Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
Lung Cancer 41:S3-8. 2003..If true, clinicians might then possess the ability to predict a tumor's clinical behavior and shape its density through specific, targeted interventions...
- Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10Andrea Bezjak
National Cancer Institute of Canada Clinical Trials Group, Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
J Clin Oncol 26:5052-9. 2008..We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC...
- Summary report 7th Annual Targeted Therapies of the Treatment of Lung CancerLawrence H Einhorn
Indiana Cancer Pavilion, Indianapolis, Indiana, USA
J Thorac Oncol 3:545-55. 2008
- The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxibMary J Fidler
Rush University Medical Center, Chicago, Illinois 60612, USA
Clin Cancer Res 14:2088-94. 2008..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
- Does gefitinib shorten lung cancer survival? Chaos reduxVicki L Keedy
J Clin Oncol 26:2428-30. 2008
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:1472-8. 2008..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
- Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group StudyAfshin Dowlati
University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA
Clin Cancer Res 14:1407-12. 2008....
- Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599Suresh S Ramalingam
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
J Clin Oncol 26:60-5. 2008..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
- A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)Kishan J Pandya
James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
J Thorac Oncol 2:1036-41. 2007..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer...
- Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancerJeffrey M Albert
Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007..Previous studies have examined the prognostic value of clusterin expression in various malignancies. In the present study, we examined clusterin staining in tumors resected from patients with non-small cell lung cancer (NSCLC)...
- Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancerLi Yang
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Cancer Res 67:5587-93. 2007..This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI...
- Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonismLi Yang
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Cancer Res 66:9665-72. 2006..Selective antagonism of the EP4 receptor may thus represent a novel therapeutic approach for the treatment of cancer and especially its propensity to metastasize...
- Targeted therapies in combination with chemotherapy in non-small cell lung cancerDavid H Johnson
Vanderbilt Ingram Cancer Center and Division of Hematology and Oncology, Vanderbilt University School of Medicine Nashville, Tennessee 37232 6307, USA
Clin Cancer Res 12:4451s-4457s. 2006..However, in the absence of such biomarkers, clinical judgment, common sense, and innovative clinical trial design are necessary to avoid undue delay in drug development...
- Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson
Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
J Clin Oncol 22:2184-91. 2004..To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer...
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2Roy S Herbst
Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
J Clin Oncol 22:785-94. 2004..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1Giuseppe Giaccone
Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
J Clin Oncol 22:777-84. 2004..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
- Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598Corey J Langer
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 22:1180-7. 2004..The Eastern Cooperative Oncology Group therefore launched a phase II study evaluating combination carboplatin, paclitaxel, and trastuzumab in patients with advanced NSCLC...
- American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003David G Pfister
American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 22:330-53. 2004
- Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancerSteven M Keller
Department of Cardiothoracic Surgery, The Montefiore Medical Center, 3400 Bainbridge Ave, Suite 5B, Bronx, NY 10467, USA
Lung Cancer 42:79-86. 2003..The majority of SPTs occur outside the aerodigestive tract. Following development of a non-skin SPT, the survival difference between patients who had received adjuvant CRT and those treated with adjuvant RT alone was not significant...
- An advance in small-cell lung cancer treatment--more or lessJanessa Laskin
J Natl Cancer Inst 95:1099-101. 2003
- Gefitinib (Iressa) trials in non-small cell lung cancerDavid H Johnson
Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232 6307, USA
Lung Cancer 41:S23-8. 2003..Further studies employing single agent gefitinib as well as regimens employing a different sequencing of chemotherapy and gefitinib are planned in recurrent and previously untreated lung cancer patients...
- Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 21:2094-100. 2003..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients...
- Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?David H Johnson
J Clin Oncol 21:2227-9. 2003
- Novel therapies for the treatment of non-small cell lung cancerDavid H Johnson
Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232 6307, USA
Cancer Chemother Biol Response Modif 20:763-86. 2002..In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!..
- Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592David T Eton
Evanston Northwestern Healthcare and Northwestern University, Evanston, IL 60201, USA
J Clin Oncol 21:1536-43. 2003..To determine the ability of longitudinal patient-reported health (PRH) scores to enhance prediction of clinical outcomes beyond baseline scores...
- Improving the evaluation of new cancer treatments: challenges and opportunitiesMace L Rothenberg
Vanderbilt Ingram Cancer Center, 777 Preston Research Building, Nashville, Tennessee 37232 6307, USA
Nat Rev Cancer 3:303-9. 2003..How can clinical trials be re-designed to accommodate the new features of targeted anticancer drugs?..
- Seminars in oncology. IntroductionPaul A Bunn
Department of Medicine, University of Colorado Cancer Center, Denver, CO 80262, USA
Semin Oncol 29:1-2. 2002
- Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trialCorey J Langer
C J Langer, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Natl Cancer Inst 94:173-81. 2002....
- Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerAlan B Sandler
Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Clin Cancer Res 10:4258s-4262s. 2004..These studies will help to establish the role of bevacizumab in NSCLC...
- Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller
Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
J Thorac Cardiovasc Surg 128:130-7. 2004....
- Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancerLaine J Murphey
Division of Clinical Pharmacology, Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Anal Biochem 334:266-75. 2004..In summary, quantification of PGE-M using LC/MS/MS provides a facile and accurate method to assess PGE2 formation in human physiological and pathophysiological processes...
- Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agentsThomas J Lynch
Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
Clin Cancer Res 12:4365s-4371s. 2006
- Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990Heather A Wakelee
Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
Cancer 106:2208-17. 2006....
- Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancerIldiko Csiki
Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6838, USA
Cancer Res 66:143-50. 2006..We also show that thioredoxin-1 stabilizes HIF-1alpha to induce hypoxia-responsive genes under normoxic conditions. Our results identify two new mechanisms for regulation of COX-2 expression in NSCLC...
- Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trialsDaphne W Bell
Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA
J Clin Oncol 23:8081-92. 2005..The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib...
- Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxelIldiko Csiki
Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
Clin Cancer Res 11:6634-40. 2005..However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted...
- TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst
University of Texas M D Anderson Cancer Center, Houston, USA
J Clin Oncol 23:5892-9. 2005..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
- Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard
Department of Pathology, Genentech Inc, San Francisco, CA, USA
J Clin Oncol 23:5900-9. 2005..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
- Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancerDong Wook Kim
Department of Radiation Oncology, Vanderbilt University Medical Center, TN, USA
Lung Cancer 50:235-45. 2005..We sought to determine mature data from this database of patients, as well as to perform analysis of a cohort of patients who have achieved long term survival (LTS) when treated with this regimen...
- Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancerDong Wook Kim
Department of Radiation Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN, USA
Int J Radiat Oncol Biol Phys 63:1029-36. 2005..Therefore, we sought to determine the impact of the response rate on survival for patients who were treated with combined modality therapy for LANSCLC...
- Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology GroupHeather A Wakelee
Stanford Clinical Cancer Center, 875 Blake Wilbur Drive, Room 2231, Stanford, CA 94305 5826, USA
Lung Cancer 48:389-97. 2005..The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT...
- Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunitiesVincent A Miller
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Room 1012 H Building, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 23:3288-93. 2005....
- Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell luChandra P Belani
University of Pittsburgh Medical Center Cancer Pavilion, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
J Clin Oncol 23:3760-7. 2005..To compare once-daily radiation therapy (qdRT) with hyperfractionated accelerated radiation therapy (HART) after two cycles of induction chemotherapy...
- Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancRoy S Herbst
Department of Thoracic Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
J Clin Oncol 23:2544-55. 2005..Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC)...
- Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphomaDouglas W Blayney
Wilshire Oncology Medical Group, Inc, Pasadena, California, USA
Oncologist 10:138-49. 2005..We conclude that the delivery of myelosuppressive chemotherapy in both a dose-intense and a dose-dense manner is feasible with filgrastim support...
- Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group dataTien Hoang
University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
J Clin Oncol 23:175-83. 2005....
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerJoan H Schiller
University of Wisconsin Hospital and Clinics, Madison, USA
N Engl J Med 346:92-8. 2002..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...